Science · SV2A platform
SV2A is the one target that reports on synapses everywhere in the brain.
Synaptic vesicle glycoprotein 2A is expressed on essentially every synaptic vesicle. Quantifying its density with PET gives a direct, pan-disease measure of synaptic integrity — the earliest functional change in neurodegeneration, measurable while people are still cognitively normal.
Human evidence in hand
−41%hippocampal SV2A in Alzheimer's disease (Chen et al., JAMA Neurol. 2018).
−39%in substantia nigra in Parkinson's disease — 30 PD vs 30 healthy controls, p = 0.003 (Li 2026).
−27%in red nucleus in the same Parkinson's cohort, p = 0.009 (Li 2026).
50+published human studies across 1,700+ participants; 34 registered clinical trials.
17indications under study — Alzheimer's, Parkinson's, epilepsy, depression, schizophrenia and more. One target, pan-disease.
R = 0.56Synaptic density is a strong predictor of cognitive performance (Mecca 2022, n = 45); hippocampal SV2A binding tracks episodic memory, p = .01 (Chen 2018).
TARGET
SV2A on every synaptic vesicle
READOUT
Synaptic density, quantitative (V_T)
VALIDATION
Post-mortem synaptophysin, FNIH
SV2A PET · V_T · AXIAL / CORONAL / SAGITTALHEALTHY HUMAN · TEST–RETEST
Two scans of the same healthy participant — the near-identical maps are the test–retest reproducibility that makes SV2A PET quantitative. Colour scale: V_T 0–40. (Löscher et al. 2016)
Built for scale
110-MINUTE HALF-LIFE
Fluorine-18 allows central production and hub-and-spoke shipping to PET centers — no on-site cyclotron required.
SIMPLE PROTOCOL
Quantitative readout with published test–retest variability under 9%.
EXISTING INFRASTRUCTURE
¹⁸F radiopharmacy networks already deliver tracers to PET centers nationwide every morning. We plug into that infrastructure rather than build it.
SynVesT is investigational and not approved for clinical use. Figures cited from published literature.